<DOC>
	<DOCNO>NCT00004187</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine capecitabine oxaliplatin treat patient advanced metastatic colorectal cancer surgically remove .</brief_summary>
	<brief_title>Capecitabine Oxaliplatin Treating Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose capecitabine combine oxaliplatin patient chemotherapy naive thymidylate synthase inhibitor pretreated unresectable , advanced metastatic colorectal cancer . II . Determine safety profile , toxicity , efficacy regimen patient . III . Determine complete partial remission rate , time treatment failure , overall survival patient treat regimen . OUTLINE : This dose escalation , multicenter study capecitabine . Patients stratify pretreatment status ( pretreatment v chemotherapy naive v thymidylate synthase inhibitor pretreatment ) . Phase I : Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine every 12 hour day 1-14 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define high dose 2 6 patient experience dose limit toxicity . Phase II : Patients receive capecitabine feasible dose . The feasible dose define dose immediately precede MTD phase I . Patients follow every 3 month 1 year , every 6 month thereafter death . PROJECTED ACCRUAL : Approximately 18 patient accrued phase I study total 27-68 patient ( 14-25 thymidylate synthase inhibitor pretreated patient 13-43 chemotherapy naive patient ) accrue phase II study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven unresectable , advanced metastatic colorectal cancer Measurable disease Phase I : Any pretreatment status Phase IIN ( chemotherapy naive patient ) : No prior chemotherapy advance metastatic cancer prior adjuvant chemotherapy OR No prior chemotherapy advance metastatic cancer prior adjuvant chemotherapy end 6 month ago Phase IIP ( thymidylate synthase inhibitor pretreated patient ) : No thymidylate synthase inhibitor base regimen advance metastatic cancer prior adjuvant chemotherapy end less 6 month ago OR One thymidylate synthase inhibitor base regimen advance metastatic cancer adjuvant thymidylate synthase inhibitor base regimen OR One thymidylate synthase inhibitor base regimen advance metastatic cancer one additional adjuvant thymidylate synthase inhibitor base regimen end 6 month ago No CNS metastases PATIENT CHARACTERISTICS : Age : 18 75 Performance status : 0 1 Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN ( 5 time ULN relate liver metastasis ) Renal : Creatinine great 1.25 time ULN Cardiovascular : No New York Heart Association class III IV heart disease No congestive heart failure No symptomatic coronary artery disease No cardiac arrhythmia unless well control medication No myocardial infarction within past 12 month Neurologic : No peripheral neuropathy origin bad grade 1 No prior concurrent seizure CNS disorder require treatment Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No dysphagia , malabsorption , intestinal obstruction could impact absorption excretion study drug No psychiatric disability precluding inform consent compliance No prior malignancy within past 5 year except adequately treat carcinoma situ cervix localize nonmelanomatous skin cancer No significant medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : At least 4 week since prior major gastrointestinal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>